Brokerages Set Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) PT at $22.13

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) has received a consensus recommendation of “Moderate Buy” from the nine analysts that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $22.1250.

A number of equities analysts recently commented on the stock. Lifesci Capital raised shares of Compass Pathways to a “strong-buy” rating in a research note on Thursday, February 12th. Compass Point set a $15.00 target price on Compass Pathways in a research report on Thursday, February 12th. Morgan Stanley lifted their price target on Compass Pathways from $11.00 to $18.00 and gave the company an “overweight” rating in a report on Wednesday, February 18th. Canaccord Genuity Group boosted their price target on Compass Pathways from $15.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, February 18th. Finally, HC Wainwright upped their price objective on Compass Pathways from $40.00 to $70.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd.

Institutional Trading of Compass Pathways

Hedge funds have recently modified their holdings of the company. RTW Investments LP boosted its holdings in shares of Compass Pathways by 0.6% in the 4th quarter. RTW Investments LP now owns 8,757,390 shares of the company’s stock valued at $60,426,000 after buying an additional 50,000 shares in the last quarter. Nantahala Capital Management LLC raised its stake in shares of Compass Pathways by 47.7% during the 2nd quarter. Nantahala Capital Management LLC now owns 4,179,930 shares of the company’s stock worth $11,704,000 after acquiring an additional 1,350,698 shares in the last quarter. Millennium Management LLC raised its stake in shares of Compass Pathways by 39.9% during the 3rd quarter. Millennium Management LLC now owns 2,715,872 shares of the company’s stock worth $15,562,000 after acquiring an additional 774,090 shares in the last quarter. Toronto Dominion Bank lifted its position in Compass Pathways by 152.9% during the fourth quarter. Toronto Dominion Bank now owns 2,529,013 shares of the company’s stock valued at $17,447,000 after acquiring an additional 1,529,013 shares during the last quarter. Finally, ARK Investment Management LLC boosted its stake in Compass Pathways by 1.6% in the fourth quarter. ARK Investment Management LLC now owns 2,156,012 shares of the company’s stock valued at $14,876,000 after acquiring an additional 34,894 shares in the last quarter. 46.19% of the stock is owned by hedge funds and other institutional investors.

Compass Pathways Price Performance

Shares of CMPS opened at $6.06 on Friday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.23 and a current ratio of 1.23. The company has a 50 day moving average price of $6.97 and a 200-day moving average price of $6.28. Compass Pathways has a fifty-two week low of $2.25 and a fifty-two week high of $8.90. The stock has a market capitalization of $581.88 million, a PE ratio of -2.23 and a beta of 1.90.

About Compass Pathways

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.